Abstract
Whether cyclin D1 (CCND1) gene variants increase susceptibility to head and neck cancer (HNC) is undetermined. Therefore, we performed the present meta-analysis to systematically assess any possible association between CCND1 variants (G870A and G1722C) and HNC risk. Seventeen studies for CCND1 G870A and three studies for CCND1 G1722C were included. Overall, CCND1 polymorphisms (G870A and G1722C) had no association with increased HNC risk (p>0.05). In the subgroup analysis by smoking status, significantly increased HNC risk was found among smokers under allele contrast, homozygous comparison and recessive models (p<0.05), smoking carriers of A allele and AA genotype appearing at elevated risk. In conclusion, while there was overall a lack of any association between CCND1 polymorphisms (G870A and G1722C) and HNC risk, smokers carrying the A allele and AA genotype of the CCND1 G870A polymorphism may be susceptible to HNC development.
Highlights
Head and neck cancers (HNC) comprising malignant neoplasms of the oral cavity, pharynx, and larynx, are the sixth most common cancers which threatens human life worldwide (Jemal et al, 2010)
19 potentially appropriate papers reported the association of cyclin D1 (CCND1) polymorphisms (G870A and G1722C) with the risk of HNC
CCND1 G870A and G1722C polymorphisms had no association with increased HNC risk under all five genetic models (p>0.05)
Summary
Head and neck cancers (HNC) comprising malignant neoplasms of the oral cavity, pharynx, and larynx, are the sixth most common cancers which threatens human life worldwide (Jemal et al, 2010). An important one is a cell cycle regulatory gene called cyclin D1 (CCND1), which is located on chromosome 11q13 and encodes CCND1 protein, which plays a pivotal role in regulating the cell cycle at the G1 to S phase transition in the process of cell division and up-regulation of CCND1 has been proved to disrupt normal cell cycle control and participate in the oncogenesis of lung cancer and breast cancer (Cui et al, 2012, Li et al, 2012). Carries of CCND1 A allele may have a longer half-life and bypass the G1/S checkpoint more than the G allele, and is crucial in the carcinogenesis and development of brain tumors (Zeybek et al, 2013). A second common variant at nucleotide 1722 within CCND1 3 UTR, CCND1 G1722C, has been proved to be associated with urothelial cancer risk (Lin et al, 2011)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
